Genentech Newswire

Genentech Newswire

Comprehensive Real-Time News Feed for Genentech.

Results 1 - 20 of 407 in Genentech

  1. Dalradian Announces Results of Its 2016 Meeting of ShareholdersRead the original story w/Photo

    16 hrs ago | Market Wire

    Dalradian Resources Inc. is pleased to announce the results of its 2016 annual and special meeting of shareholders held today in Toronto, Ontario. At the Meeting, all director nominees listed in the Company's management information circular dated May 13, 2016 were elected as directors of the Company.

    Comment?

  2. UPDATE 1-U.S. Supreme Court refuses to review prenatal test patent disputeRead the original story

    21 hrs ago | Reuters

    The U.S. Supreme Court on Monday rejected a bid to review a legal fight over the cancellation of a patent on a less-risky form of prenatal testing, in a case that has left many companies and trade groups worried that important discoveries may no longer qualify for patents. The decision by the Supreme Court leaves intact a ruling by a federal court to invalidate Sequenom Inc's patent in an infringement dispute with rival Ariosa Diagnostics, a unit of Roche Holding AG.

    Comment?

  3. Safety Evaluation of CNS Administered Biologics--Study Design, Data...Read the original story

    21 hrs ago | Toxicological Sciences

    a 1To whom correspondence should be addressed at Genentech, Inc., 1 DNA Way, South San Francisco, California 94080. Fax: 650-866-2621. E-mail: Many central nervous system (CNS) diseases are inadequately treated by systemically administered therapies ...

    Comment?

  4. Preclinical Safety Profile of a Depleting Antibody against CRTh2 for...Read the original story

    21 hrs ago | Toxicological Sciences

    a 5To whom correspondence should be addressed at Department of Pathology, Genentech Inc., Mail Stop 72B, 1 DNA Way, South San Francisco, California 94080. Fax: CRTh2 is expressed on immune cells that drive asthma pathophysiology. Current treatment ...

    Comment?

  5. FY2016 EPS Estimates for Dalradian Resources Inc (DNA) Decreased by AnalystRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    Dalradian Resources Inc - Beacon Securities reduced their FY2016 earnings estimates for Dalradian Resources in a research report issued to clients and investors on Thursday. Beacon Securities analyst M. Curran now expects that the firm will earn per share for the year, down from their previous forecast of .

    Comment?

  6. Dalradian Resources' (DNA) Buy Rating Reaffirmed at Numis Securities LtdRead the original story w/Photo

    Saturday Jun 25 | AmericanBankingNews.com

    's stock had its "buy" rating reaffirmed by equities research analysts at Numis Securities Ltd in a research report issued on Tuesday, StockTargetPrices.com reports. Dalradian Resources traded up 1.92% on Tuesday, reaching $1.06.

    Comment?

  7. Global Novel Drug Delivery Systems (NDDS) Market Was Valued at USD...Read the original story

    Thursday Jun 23 | PR.com

    ... Inc., Bayer AG, Boehringer Ingelheim, Boston Scientific, Bristolmyers Squibb, Celgene Corporation, Cephalon, Inc., Genentech Inc., Genzyme Corporation, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding AG, ...

    Comment?

  8. RPT-U.S. Supreme Court weighs review of canceled patent on prenatal testRead the original story

    Thursday Jun 23 | Reuters

    Companies, trade groups and universities who fear that many important discoveries may no longer qualify for patents are among a broad coalition urging the U.S. Supreme Court to review the cancellation of a patent on a less risky form of prenatal testing. The justices are set to consider on Thursday whether to take the case involving biotechnology company Sequenom Inc's patent, which was thrown out in 2013 during infringement litigation with rival Ariosa Diagnostics, a unit of Roche Holding AG.

    Comment?

  9. GrayBug Expands Executive Team With Appointments Of MD, And PhDRead the original story

    Tuesday Jun 21 | BioSpace

    ... product company ForSight VISION5, Inc., where he was the Chief Medical Officer. He began his industry career at Genentech, Inc., first working as Medical Director in Cardiac & Vascular Biotherapeutics and later as Senior Group Director in ...

    Comment?

  10. Epizyme and Genentech to assess tazemetostat/Tecentriq combo in blood cancer, study to start in H2Read the original story w/Photo

    Wednesday Jun 22 | Seeking Alpha

    Epizyme and Roche's Genentech will collaborate on a Phase 1b clinical trial to evaluate the combination of tazemetostat and Tecentriq for the treatment of relapsed/refractory diffuse large B-cell lymphoma . Under the terms of the agreement, the companies will supply their respective products and equally share the costs of the study.

    Comment?

  11. Graybug Vision Expands Executive Team With Appointments of Charles P. ...Read the original story w/Photo

    Tuesday Jun 21 | Market Wire

    ... product company ForSight VISION5, Inc., where he was the Chief Medical Officer. He began his industry career at Genentech, Inc., first working as Medical Director in Cardiac & Vascular Biotherapeutics and later as Senior Group Director in ...

    Comment?

  12. Hot Tips For the Next Disruptive Blood Testing UnicornRead the original story w/Photo

    Wednesday Jun 8 | Wired

    ... it is done," says Stephanie Eberle , director of Stanford Medicine's careers center. She points to companies like Genentech, which began as a venture capital-funded startup in the 1970s. Sure, they were doing recombinant DNA, not blood tests. But ...

    Comment?

  13. Global Next Generation Sequencing Market 2016 Share, Trend, Segmentation and Forecast to 2022Read the original story

    Tuesday Jun 14 | World News Report

    PUNE, INDIA, June 14, 2016 / EINPresswire.com / -- The Global Next Generation Sequencing Market accounted for $2.8 billion in 2014 and is expected to grow at a CAGR of 21.7 % to reach $13.5 billion by 2022. Next-generation sequencing enables rapid sequencing and produces millions of DNA and RNA sequences.

    Comment?

  14. Alkermes and Genentech Expand Collaboration for Nutropin DepotRead the original story

    Dec 31, 1995 | Pharmaceutical Online

    On April 15, Genentech Inc. and Alkermes Inc. announced a two-year extension and expansion of their collaboration for Nutropin Depot, an injectable sustained release formulation of Genentech's human growth hormone based on Alkermes' ProLease drug delivery system. As anticipated by their original collaboration, initiated in 1995, the companies have completed a Phase III clinical trial of Nutropin Depot for the treatment of pediatric growth hormone deficiency and are preparing to submit a New Drug Application with the U.S. Food and Drug Administration .

    Comment?

  15. Chronic Urticaria Or Hives Pipeline Report H1 2016 - Review of...Read the original story

    Friday Jun 10 | Emailwire.com

    ... Involved in Therapeutics Development 15 AstraZeneca Plc 15 Biofrontera AG 16 ELORAC, Inc. 17 Faes Farma, SA 18 Genentech, Inc. 19 Contact Us: Mr. Nachiket Albany NY - 12207 United States Tel: +1-518-621-2074 Tel: 866-997-4948 (Us-Canada Toll Free) ...

    Comment?

  16. Venture Capitalist Legend Thomas Perkins DiesRead the original story w/Photo

    Thursday Jun 9 | Wall Street Journal

    ... in young companies, betting that some would grow into tech giants. As an investor, perhaps his biggest success was Genentech Inc., the biotech company founded in 1976 and acquired by Roche Holding for $46.8 billion in 2009. He also led investments ...

    Comment?

  17. The Wall Street Journal: Venture capital legend Tom Perkins dies at 84Read the original story w/Photo

    Thursday Jun 9 | MarketWatch

    ... in young companies, betting that some would grow into tech giants. As an investor, perhaps his biggest success was Genentech Inc., the biotech company founded in 1976 and acquired by Roche Holding AG for $46.8 billion in 2009. He also led ...

    Comment?

  18. S.I. native awarded $10M in whistleblower case over cancer drugRead the original story w/Photo

    Wednesday Jun 8 | SILive.com

    ... (Photo provided by Shields) Brian Shields, 44, a Monsignor Farrell graduate from Arrochar, was working at Genentech, Inc. for four years when he decided to disclose what he perceived to be the company's misrepresentation of the effectiveness of the ...

    Comment?

  19. Drugmakers pay $67 million to settle claims they exaggerated cancer drug's effectivenessRead the original story w/Photo

    Tuesday Jun 7 | Los Angeles Times

    Genentech and another drugmaker will pay $67 million to settle claims that they misled doctors into prescribing a treatment to lung cancer patients for whom the companies knew it would not work. As a result, some patients may have died earlier than they would have if they had taken more effective drugs, a lawsuit brought by a former Genentech employee and joined by federal prosecutors alleges.

    Comment?

  20. Pharma Firms Reach $67M Deal With FedsRead the original story

    Tuesday Jun 7 | Courthouse News Service

    Drugmaker Genentech and another pharmaceutical company will pay $67 million to settle a federal lawsuit accusing them of overstating the effectiveness of cancer drug Tarceva, the Justice Department said. Federal prosecutors claim that from 2006 through 2011, Genentech and co-defendant OSI Pharmaceuticals made misleading statements to doctors about how well the drug worked for patients with non-small cell lung cancer.

    Comment?